Skip to main content
Fig. 6 | BMC Biotechnology

Fig. 6

From: Oral delivery of Sunitinib malate using carboxymethyl cellulose/poly(acrylic acid-itaconic acid)/Cloisite 30B nanocomposite hydrogel as a pH-responsive carrier

Fig. 6

(a) The percentage cell viability of the normal human fibroblastic cells (L929) cell lines for 24, 48 and 72 h incubation with drug@Hyd, drug@Hyd/Cloisite 30B, and pure Sunitinib malate and Cell viability of MCF-7 human breast cancer cell in (b) the beginning of the experiment (c) after treating with drug@Hyd/Cloisite 30B for 72 h

Back to article page

BMC Biotechnology

ISSN: 1472-6750

Contact us